Molecular Diagnostic Techniques Overview

Principles

Definition

Molecular diagnostic techniques is a field and methodological approach focused on the analysis of biological molecules such as nucleic acids and proteins to identify molecular signatures indicative of disease states, predisposition, or therapeutic response, providing highly specific and sensitive diagnostic information for clinical or research purposes.

Ontological type

Core Methods

Clinical Applications

Analytical Performance

Key developments

Key Figures

Biorecognition Diagnostics era

Frank J. Dixon [1] was a central figure in the Biorecognition Diagnostics era (1949–1987), with affiliations at Rockefeller University [2] and Harvard University [3] during this period. Dixon [1], through the paper A Method of Trace Iodination of Proteins for Immunologic Studies [4], helped establish a practical approach to label proteins for immunologic investigations, enabling detection of binding events and the translation of molecular recognition into measurable signals. This lineage of work at Rockefeller University [2] and Harvard University [3], led by Frank J. Dixon [1], contributed to the development of standardized assay formats and labeled-detection chemistries that underpinned biorecognition-based diagnostics in the era. The 1966 trace iodination method [4] provided a concrete framework for converting antigen–antibody interactions into assessable signals, accelerating adoption of standardized immunoassays in clinical laboratories.

Nucleic Acid Amplification era

Francis S. Collins [1], with ties to the American College of Medical Genetics [3] and Harvard University [4], stood as a central figure in shaping molecular diagnostics during this era. His landmark paper, Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA [6], demonstrated how gene-level characterization could enable targeted diagnostics and catalyzed the shift toward rapid, amplification‑based testing in this era. Paul D. N. Hebert [2], affiliated with Harvard University [4] and the Icahn School of Medicine at Mount Sinai [5], embodies the era's emphasis on practical DNA processing approaches. His 2006 paper An inexpensive, automation‑friendly protocol for recovering high‑quality DNA [7] contributed to scalable, automation-ready workflows that improved DNA recovery from clinical samples and supported robust amplification and rapid diagnostic turnaround.

Sequencing and Multiplexing era

Janice S. Chen [1], Innovative Genomics Institute [3], and Harvard University [4] stand among the era's leading forces shaping sequencing-driven multiplexed diagnostics. Her key contributions center on CRISPR-Cas12a target binding and the resulting indiscriminate single-stranded DNase activity, as documented in the 2018 paper CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity [6], which laid a mechanistic foundation for rapid, multiplexable nucleic acid detection within sequencing workflows. Jennifer A. Doudna [2], Innovative Genomics Institute [3], and University of California, San Francisco [5] helped propel CRISPR-based diagnostics within high-throughput sequencing contexts during this era. The 2018 CRISPR-Cas12a paper CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity [6] underscores their shared impact in this era, illustrating how programmable nucleases enable simultaneous, information-rich reads that accelerate diagnostic breadth, validation, and clinical integration across multiplex platforms.